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Abstract
Little is known about impulse oscillometry (IOS) in COPD. IOS is an effort independent measure of lung resistance and 
reactance (compliance). We assessed how frequency dependence of resistance (R) and reactance (X) changed in response to 
bronchoconstriction with carvedilol followed by long acting beta-agonist (LABA) withdrawal. N = 12 patients with moder-
ate to severe COPD were analysed, who had ≥ 100 ml fall in  FEV1 with carvedilol. Compared to baseline taking ICS/LABA 
there were 21, 59, and 135% significant changes in resistance at 5 Hz (R5), reactance at 5 Hz (X5), and reactance area (AX), 
respectively, with carvedilol, while after LABA withdrawal only AX showed a further significant increase to 210% (i.e. 
reduced compliance). Hence changes in lung compliance rather than resistance play a more important role in the beta-2 
receptor-mediated responses in COPD.
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Introduction
Little is known about impulse oscillometry (IOS) in COPD. 
Current diagnosis and management of the disease relies 
heavily on spirometry, specifically the forced expiratory 
volume in 1 s  (FEV1) and forced vital capacity (FVC) to 
assess severity of airflow obstruction. Spirometry unlike IOS 
is effort dependent and is therefore susceptible to artificial 
effects of forced expiratory airway closure. IOS is more 
physiologic being performed with normal tidal breathing, 
using sound waves of varying frequencies to detect changes 
in respiratory resistance (R) and reactance (X). In this 
regard, reactance and compliance are related in reciprocal 
manner. Changes in airway compliance are thought to reflect 
the degree of hyperinflation in COPD [1].
A post hoc analysis of ECLIPSE in 2054 patients with 
COPD demonstrated that airway resistance at 5 Hz but not 
20 Hz increased modestly comparing GOLD groups 2 and 4, 
but airway compliance (as integrated area of low frequency 
reactance, AX) increased by a much larger degree [2]. Fur-
thermore healthy controls and smokers had mean AX values 
of 0.38 and 0.34 kPa/L/s Hz, whereas even GOLD group 2 
patients had a mean AX of 1.37 kPa/L/s Hz, in turn suggest-
ing that reduced lung compliance plays an important role in 
the early pathophysiology of the disease.
Airway compliance as AX or reactance at 5 Hz (X5) has 
been shown to be closely associated with changes in  FEV1 
[2, 3], more so than resistance as R5. There are few data on 
changes in IOS in response to bronchoconstrictor stimuli in 
patients with COPD. In one study, there was discordance 
between R5 and X5 in response to methacholine bronchoc-
onstriction in COPD, while in asthma there was concordance 
in response [4].Sunny Jabbal and Brian J. Lipworth have contributed equally to 
the work and have read and approved the submission.
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Methods
Here, we report on a post hoc responder analysis of the 
carvedilol arm of NCT01656005 [5]. This study had 
favourable opinion from the East of Scotland Research 
and Ethics Committee (12/ES/0054). In brief, patients 
with moderate to severe COPD received an initial run-
in of 2 weeks with ICS/LABA as beclometasone 100 µg/
formoterol 6 µg 2 puffs bid (Fostair, Chiesi, Manchester, 
UK). At baseline after run-in, while still receiving ICS/
LABA, patients received weekly dose titration with the 
non-selective beta-blocker carvedilol to achieve a target 
dose of 12.5 mg bid, which was then given in conjunction 
with a further 1 week on ICS/LABA. This was followed 
by LABA withdrawal with a further week to ICS alone 
as beclometasone 200 µg 2 puffs bid (Clenil, Chiesi) in 
the presence of continued carvedilol. Patients had lung 
function tests at baseline (SuperSpiro, Micro Medical Ltd, 
Chatham, Kent, United Kingdom) and IOS (Jaeger Mas-
terscreen IOS, Hochberg, Germany) on no beta-blocker 
while taking ICS//LABA and subsequently while taking 
carvedilol in conjunction with ICS/LABA and ICS alone.
We carried out a responder analysis, selecting those 
patients (n = 12) who exhibited a decrease in  FEV1 of 
≥ 100 ml, i.e. above the MCID [6] in response to carve-
dilol while taking concomitant ICS/LABA. We calculated 
percentage change in AX, X5, R5, R20,  FEV1 and FVC 
comparing pre beta-blocker baseline (on ICS/LABA) to 
carvedilol plus either ICS/LABA or ICS alone. We also 
calculated standardised response means (SRM), which are 
a relative measure of effect size and responsiveness and 
so express the signal (mean)-to-noise (standard deviation) 
ratio [7]. An SRM of 0.8 units or greater is considered 
highly sensitive, and because they are standardised scores, 
they can be compared between variables [7].
Results
Patients had a mean age 65 years, mean smoking pack 
year history of 53, mean  FEV1 52% predicted, and mean 
7% reversibility of  FEV1 to salbutamol 400 µg. Percent-
age change from baseline in IOS (R5, R20, X5, AX) and 
 FEV1 are depicted in Fig. 1. In terms of airway resistance, 
R5 increased significantly from the presence of carve-
dilol, while no further increase in R5 occurred when the 
LABA was withdrawn. In contrast, there was no significant 
change in R20 at any point.
In terms of reactance, there was a significant increase 
(i.e. reduced compliance) in both X5 and AX in the 
presence of carvedilol, however only AX increased 
significantly more after LABA withdrawal.  FEV1 
decreased significantly in the presence of carvedilol and 
decreased significantly further after LABA withdrawal, 
while FVC was only reduced after LABA withdrawal. 
SRM’s (Table 1) for reactance were higher than those for 
resistance, with AX being greater than X5.
Discussion
In patients receiving ICS/LABA, carvedilol challenge pro-
duced no significant change in R20, in turn suggesting that 
larger airways are not involved in β2-mediated bronchocon-
striction in COPD. Previous data have also shown that R20 
is unrelated to airflow obstruction or lung hyperinflation in 
COPD [3, 8]. It is known that LABA reduces lung hyper-
inflation [9] as measured by RV, and that in turn reactance 
is related to RV—in other words hyperinflation and com-
pliance appear to go hand in hand [10]. This is supported 
by using FVC as a surrogate for air trapping in COPD, 
where our data showed a 17% decrease in FVC compar-
ing ICS alone to ICS/LABA in the presence of carvedilol. 
It is worth pointing out that the presence of emphysema 
would be expected to increase compliance due to loss of 
elastic lung recoil [11]. However, emphysema also results in 
reduced airway support due to loss of alveolar attachments, 
manifesting as small airway closure. Hence the net result of 
reduced compliance presumably reflects the relative domi-
nance of small airways closure in response to beta-2 antago-
nism and LABA withdrawal. The finding of increased small 
airway resistance was evident as heterogeneity of resistance 
between 5 and 20 Hz (R5-20) is also in keeping with alerted 
small airways geometry.
Fig. 1  Comparison of percentage change from baseline (on ICS/
LABA without beta-blocker) in reactance (i.e. compliance: AX, X5) 
and resistance (R5, R20), and forced expiratory volume in 1 s  (FEV1). 
Asterisk denotes P < 0.05 versus baseline, cross denotes P < 0.05 ver-
sus ICS/LABA
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In terms of bronchodilator response in COPD, tiotropium 
and tulobuterol have been shown to produce significantly 
additive effects on X5, AX, R5 but not R20 [8]. Accordingly 
in terms of bronchoconstriction in our patients, there was a 
significant increase in R5, but not R20, and an increase in 
AX, and X5. This was in keeping with the ECLIPSE cohort, 
where AX rather than R5 more closely followed COPD 
severity defined by FEV1, while R20 was unchanged [2]. 
Our data were also similar to in TORCH [12], where ICS/
LABA was significantly different to ICS alone on  FEV1. 
This is perhaps unsurprising since our patients were selected 
a priori on the basis of a fall in FEV1 while taking ICS/
LABA with carvedilol. In terms lung compliance, both AX 
and X5 increased significantly after carvedilol; however, 
only AX significantly increased after removal of LABA. AX 
represents lung compliance component of low-frequency-
dependent reactance, and appears to be more sensitive than 
reactance measured at 5 Hz (X5), for identifying increasing 
changes in response to combined β2-receptor antagonism 
and agonism.
The limitations of our analysis are its small sample size, 
and lack of corroboration of reactance (AX, X5) with static 
lung volumes such as RV/TLC ratio. Moreover, we did not 
measure the within breath differences between inspiratory 
and expiratory reactance as a measure of dynamic hyperin-
flation, for the pragmatic reason that this is not performed 
in our routine clinical practice. We also acknowledge that 
we did not perform CT imaging to define the degree of 
emphysema nor did we evaluate ventilation heterogeneity 
using multiple breath nitrogen washout. Nonetheless, using 
FVC as a crude surrogate for air trapping, we did observe a 
significant reduction in response to carvedilol in conjunction 
with LABA withdrawal.
This analysis provides evidence that reduced lung com-
pliance (as AX) measured by IOS is a sensitive outcome 
in response to bronchoconstriction in COPD. It would be 
relevant to know if exacerbation frequency and symptoms 
are more closely related to alterations in compliance than 
resistance, and in turn whether lung compliance might be a 
potential target for long acting bronchodilator therapy, for 
example comparing ICS/LABA/LAMA to ICS/LABA.
Funding The study was partially funded by TENOVUS Scotland 
(Grant No. T12/28) as well as from existing departmental unrestricted 
grant funds.
Compliance with Ethical Standards 
Conflict of interest Dr. Jabbal reports personal fees and non-financial 
support from Chiesi Pharma, personal fees and non-financial support 
from Pfizer, non-financial support and other from Napp, personal 
fees and non-financial support from AstraZeneca, personal fees from 
Boehringer Ingelheim, non-financial support from TEVA, outside the 
submitted work. Dr. Lipworth reports grants, personal fees and non-
financial support from Chiesi, grants, personal fees, non-financial sup-
port and other from Boehringer Ingelheim, grants and personal fees 
from Meda, grants, personal fees and non-financial support from Teva, 
grants from Janssen, grants from AstraZeneca, grants from Roche, per-
Table 1  Mean (95% CI) differences as change from baseline (on 
ICS/LABA without beta-blocker): in forced expiratory volume in 1 s 
(FEV1), and impulse oscillometry values of resistance (R) at 5  Hz 
(R5) and 20 Hz (R20) and reactance (X) at 5 Hz (X5) and area under 
the curve (AX), with standardised response means (SRM)
The higher the SRM the better the signal to noise ratio for a given variable. Mean baselines values were as follows: FEV1 1.43 L, FVC 3.55 L, 
R5 0.60 kPa/L/s, R20 0.39 kPa/L/s, X5 − 0.27 kPa/L/s, AX 2.69 kPa/L/s Hz
Carvedilol + ICS/LABA
Mean difference (95% CI) P SRM
FEV1 (L) − 0.21 (− 0.27, − 0.15) < 0.001 2.21
FVC (L) − 0.22 (− 0.44, − 0.01) 0.046 0.65
R5 (kPa/L/s) 0.10 (0.01, 0.19) 0.03 0.72
R20 (kPa/L/s) − 0.01 (− 0.05, 0.03) 0.55 0.18
X5 (kPa/L/s) − 0.10 (− 0.16, − 0.05) < 0.001 1.19
AX (kPa/L/s Hz) 1.46 (0.63, 2.29) < 0.001 1.11
Carvedilol + ICS
Mean difference (95% CI) P SRM
FEV1 (L) − 0.30 (− 0.39, − 0.20) < 0.001 2.08
FVC (L) − 0.60 (− 0.85, − 0.35) < 0.001 1.52
R5 (kPa/L/s) 0.11 (0.01, 0.21) 0.03 0.72
R20 (kPa/L/s) − 0.02 (− 0.07, 0.03) 0.50 0.20
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